Commentary: Hormone replacement therapy and coronary heart disease: Four lessons

International Journal of Epidemiology

Volumn 33, Issue 3, 2004, Pages 461-463

  Petitti, Diana ^a  

^a KAISER PERMANENTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEDROXYPROGESTERONE ACETATE; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; TRIACYLGLYCEROL;

BLOOD CLOTTING; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DRUG MECHANISM; EPIDEMIOLOGICAL DATA; FIBRINOLYSIS; GLUCOSE METABOLISM; HEART DEATH; HEART INFARCTION; HORMONE SUBSTITUTION; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MENOPAUSAL SYNDROME; MORBIDITY; MORTALITY; NOTE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ATTITUDE; ATTITUDE OF HEALTH PERSONNEL; CORONARY DISEASE; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; PROGESTINS; RANDOMIZED CONTROLLED TRIALS;

EID: 3242888502     PISSN: 03005771     EISSN: None     Source Type: Journal    
DOI: 10.1093/ije/dyh192     Document Type: Note

References (33)

1. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991;20:47-63. (Reprinted Int J Epidemiol 2004;33:445-53.)
2. Hulley S, Grady D, Bush T et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13.
3. Rossouw JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
4. Grady D, Herrington D, Bittner V et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002;288:49-57.
5. Herrington DM, Reboussin DM, Brosnihan KB et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000;343:522-29.
6. Angerer P, Stork S, Kothny W et al. Effect of oral postmenopausal hormone replacement on progression of atherosclerosis : a randomized, controlled trial. Arterioscler Thromb Vasc Biol 2001;21:262-68.
7. Hodis HN, Mack WJ, Lobo RA et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-53.
8. Cherry N, Gilmour K, Hannaford P et al. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 2002;360:2001-08.
9. Byington RP, Furberg CD, Herrington DM et al. Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy. Arterioscler Thromb Vasc Biol 2002;22:1692-97.
10. Waters DD, Alderman EL, Hsia J et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-40.
11. Clarke SC, Kelleher J, Lloyd-Jones H et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT atherosclerosis study. Br J Obstet Gynaecol 2002;109:1056-62.
12. Hemminki E, McPherson K. Impact of postmenopausal hormone therapy on cardiovascular events and cancer: pooled data from clinical trials. BMJ 1997;315:149-53.
13. National Institutes of Health News. National Heart, Lung, and Blood Institute. NIH asks participants in Women's Health Initiative Estrogen-alone Study to stop study pills, begin follow-up phase. 2 March 2004. http:///www.nhlbi.nih.gov
14. Coronary Drug Project. The Coronary Drug Project. Initial findings leading to modifications of its research protocol. JAMA 1970;214:1303-13.
15. The Coronary Drug Project Research Group. The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. JAMA 1973;226:652-57.
16. Ory HW. Association between oral contraceptives and myocardial infarction. JAMA 1977;237:2619-22.
17. Barrett-Connor E, Wingard DL, Criqui MH. Postmenopausal estrogen use and heart disease risk factors. JAMA 1989;261:2095-110.
18. Caine YG, Bauer KA, Barzegar S et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992;68:392-95.
19. Nabulsi AA, Folsom AR, White A et al. Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. The Atherosclerosis Risk in Communities Study Investigators. N Engl J Med 1993;328:1069-75.
20. Manolio TA, Furberg CD, Shemanski L et al. Associations of postmenopausal estrogen use with cardiovascular disease and its risk factors in older women. The CHS Collaborative Research Group. Circulation 1993;88:2163-71.
21. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
22. Koh KK, Mincemoyer R, Bui MN et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336:683-90.
23. Espeland MA, Hogan PE, Fineberg SE et al. Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Diabetes Care 1998;21:1589-95.
24. Barnabei VM, Phillips TM, Hsia J. Plasma homocysteine in women taking hormone replacement therapy: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. J Womens Health Gend Based Med 1999;8:1167-72.
25. Weed DL. Causal criteria and Popperian refutation. In: Rothman KJ (ed.). Causal Inference. Chestnut Hill MA: Epidemiology Resources Inc., 1988, p. 26.
26. Humphrey LL, Chan BK, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. Ann Intern Med 2002;137:273-84.
27. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993;137:54-63.
28. Sidney S, Petitti DB, Quesenberry CP Jr. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997;127:501-08.
29. Sourander L, Rajala T, Raiha I et al. Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet 1998;352:1965-69.
30. Marmot MG, Adelstein AM, Robinson N, Rose GA. Changing social-class distribution of heart disease. BMJ 1978;ii:1109-12.
31. Marmot MG, Kogevinas M, Elston MA. Social/economic status and disease. Ann Rev Public Health 1987;8:111-35.
32. Grodstein F, Clarkson TB, Manson JE. Understanding the divergent data on postmenopausal hormone therapy. N Engl J Med 2002;348:645-50.
33. Manson JE, Hsia J, Johnson KC et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-34.